GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs will make up for pressures on its vaccines revenue.
In a report released on February 5, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with ...
GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...
CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...
The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...
DPA International on MSN1d
Annual core operating profit increases for British pharma GSKAnnual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...
The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback